References
- Factor SA, Scullin MK, Sollinger AB, et al. Cognitive correlates of hallucinations and delusions in Parkinson’s disease. J Neurol Sci. 2014;347(1-2):316–321.
- Ffytche DH, Creese B, Politis M, et al. The psychosis spectrum in Parkinson disease. Nat Rev Neurol. 2017;13(2):81–95.
- Aarsland D, Larsen JP, Tandberg E, et al. Predictors of nursing home placement in Parkinson’s disease: a population-based, prospective study. J Am Geriatr Soc. 2000;48(8):938–942.
- Panel BtAGSBCUE. American geriatrics society 2015 updated beers criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2015;63(11):2227–2246.
- Marras C, Beck JC, Bower JH, et al. Prevalence of Parkinson’s disease across North America. NPJ Parkinsons Dis. 2018;4:21.
- Meltzer HY. Role of serotonin in the action of atypical antipsychotic drugs. Clin Neurosci. 1995;3(2):64–75.
- Barone P. Neurotransmission in Parkinson’s disease: beyond dopamine. Eur J Neurol. 2010;17(3):364–376.
- Hawkins T, Berman BD. Pimavanserin: a novel therapeutic option for Parkinson disease psychosis. Neurol Clin Pract. 2017;7(2):157–162.
- Cummings J, Isaacson S, Mills R, et al. Pimavanserin for patients with Parkinson’s disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet. 2014;383(9916):533–540.
- Hermanowicz N, Edwards K. Parkinson’s disease psychosis: symptoms, management, and economic burden. Am J Manag Care. 2015;21(10 Suppl):S199–S206.
- Fredericks D, Norton JC, Atchison C, et al. Parkinson’s disease and Parkinson’s disease psychosis: a perspective on the challenges, treatments, and economic burden. Am J Manag Care. 2017;23(5 Suppl):S83–s92.
- Stang C, Hajeb M, Camerucci E, et al. Risk of hospital admission in patients with Parkinson’s disease associated psychosis (1991-2010) [abstract]. Mov Disord. 2020;35(suppl 1). Available from: https://www.mdsabstracts.org/abstract/risk-of-hospital-admission-in-patients-with-parkinsons-disease-associated-psychosis-1991-2010/
- Wetmore JB, Li S, Yan H, et al. Increases in institutionalization, healthcare resource utilization, and mortality risk associated with Parkinson disease psychosis: retrospective cohort study. Parkinsonism Relat Disord. 2019;68:95–101.
- Martinez-Martin P, Rodriguez-Blazquez C, Forjaz MJ, et al. Neuropsychiatric symptoms and caregiver’s burden in Parkinson’s disease. Parkinsonism Relat Disord. 2015;21(6):629–634.
- Gómez-Esteban JC, Tijero B, Somme J, et al. Impact of psychiatric symptoms and sleep disorders on the quality of life of patients with Parkinson’s disease. J Neurol. 2011;258(3):494–499.
- Acadia Pharmaceuticals. Nuplazid® (pimavanserin) prescribing information. San Diego, (CA): Acadia Pharmaceuticals Inc. ; 2018.
- Connolly B, Fox SH. Treatment of cognitive, psychiatric, and affective disorders associated with Parkinson’s disease. Neurotherapeutics. 2014;11(1):78–91.
- Zahodne LB, Fernandez HH. Pathophysiology and treatment of psychosis in Parkinson’s disease: a review. Drugs Aging. 2008;25(8):665–682.
- Goldman JG, Holden S. Treatment of psychosis and dementia in Parkinson’s disease. Curr Treat Options Neurol. 2014;16(3):281.
- Seppi K, Ray Chaudhuri K, Coelho M, et al. Update on treatments for nonmotor symptoms of Parkinson’s disease-an evidence-based medicine review. Mov Disord. 2019;34(2):180–198.
- Sewell DD, Jeste DV, Atkinson JH, et al. HIV-associated psychosis: a study of 20 cases. Am J Psychiatry. 1994;151(2):237–242.
- Beckett MK, Collins RL, Burnam MA, et al. Mental health and substance abuse issues among people with HIV lessons from HCSUS. RAND Corporation, RB-9300, 2007.
- Substance Abuse and Mental Health Services Administration. Co-occurring disorders and other health conditions [published 2022 Apr 21; updated 2022 Apr 21; accessed 2022 July 29]. Available from: https://www.samhsa.gov/medication-assisted-treatment/medications-counseling-related-conditions/co-occurring-disorders
- Sterling S, Chi F, Hinman A. Integrating care for people with co-occurring alcohol and other drug, medical, and mental health conditions. Alcohol Res Health. 2011;33(4):338–349.
- Parsons LS. Performing a 1: n case-control match on propensity score [computer program]. Montreal: SAS Institute; 2004. Available from: https://support.sas.com/resources/papers/proceedings/proceedings/sugi29/165-29.pdf
- Diehr P, Yanez D, Ash A, et al. Methods for analyzing health care utilization and costs. Annu Rev Public Health. 1999;20:125–144.
- Chen JJ. Treatment of psychotic symptoms in patients with Parkinson disease. Ment Health Clin. 2017;7(6):262–270.